🧠This Week in Neuroscience: Alzheimer’s Milestone, Gene Therapy Alliances, Affordable MS Drug, and More
Explore the latest breakthroughs reshaping neuroscience and neurodegenerative care. This week’s update covers EMA support for Donanemab in early Alzheimer’s, innovative gene therapy partnerships, stem cell dosing for spinal cord injury, and digital biomarkers redefining Alzheimer’s tracking. Plus, a generic MS drug disrupts pricing, and Roche challenges pharma costs with a direct-to-consumer model.
📌 What’s Inside This Week’s Update
💊 Donanemab gets EMA backing for early Alzheimer’s
🧬 Klotho and AAVnerGene partner on next-gen gene therapies
🧠XellSmart doses first patient in iPSC spinal cord trial
📊 Cumulus digital biomarkers outperform ADAS-Cog
🔬 Alamar unveils high-sensitivity pTau detection platform
💵 CivicaScript launches $68 MS drug vs. $4,300 market price
🛒 Roche explores direct-to-consumer drug sales in U.S.
From regulatory wins to smarter diagnostics, this week’s roundup highlights innovation driving the future of neuroscience.
📢 Stay Ahead in Neuroscience Research!
✅ Like, share, and subscribe for weekly updates on neuroscience and neurodegenerative breakthroughs
#Neuroscience #Alzheimers #GeneTherapy #SpinalCordInjury #DigitalHealth #BiotechNews #MultipleSclerosis #PharmaNews #HealthcareInnovation #LucidQuest #NeurodegenerativeDiseases #Biomarkers #ClinicalTrials #FDAupdates #NeuroscienceUpdates